Catalog No.: PC-27738Not For Human Use, Lab Use Only.
Tanzisertib (CC-930) is a potent, selective, ATP-competitive and orally active c-Jun N-terminal kinase (JNK) inhibitor with IC50 of 61/5/5 nM for JNK1/2/3 respectively.
Tanzisertib (CC-930) is a potent, selective, ATP-competitive and orally active c-Jun N-terminal kinase (JNK) inhibitor with IC50 of 61/5/5 nM for JNK1/2/3 respectively.
Tanzisertib (CC-930) is selective against MAP kinases ERK1 and p38α with IC50 of 0.48 and 3.4 μM respectively.
Tanzisertib (CC-930) has Ki values of 44 nM and 6.2 nM for JNK1 and JNK2 respectively.
Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 uM).
Tanzisertib (CC-930) shows remarkable selectivity in a panel of 240 kinases, EGFR being the only non-MAP kinase inhibited more than 50% at 3 μM (IC50 = 0.38 μM).
Tanzisertib (CC-930) inhibited the production of TNFα by 23% and 77% at 10 and 30 mg/kg oral dose respectively in acute rat LPS-induced TNFα production PK-PD model.
